Based on the established anti-inflammatory effects of blocking SP signalling effect in multiple diseases (reviewed in25), further studies are needed to potentially establish the MSC-derived CD10-dependent SP degradation mechanism as a viable target in joint disease. This evidence concerns the gene TFF2 and arthropathy.